CLINICAL TRIAL

Fulvestrant for Adenocarcinoma

1 Prior Treatment
Recurrent
Refractory
Recruiting · 18+ · Female · Uniondale, NY

This study is evaluating whether a combination of two drugs may help treat breast cancer.

See full description

About the trial for Adenocarcinoma

Eligible Conditions
Uterine Neoplasms · Adenocarcinoma · Adenocarcinoma of Endometrium

Treatment Groups

This trial involves 2 different treatments. Fulvestrant is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Fulvestrant
DRUG
Abemaciclib
DRUG
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

About The Treatment

Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fulvestrant
FDA approved
Abemaciclib
FDA approved

Eligibility

This trial is for female patients aged 18 and older. You must have received 1 prior treatment for Adenocarcinoma or one of the other 2 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
The person is allowed to have any adverse effects from recent surgery, radiotherapy, chemotherapy, or hormonal therapy, as long as they are grade ≤1 show original
Patients with endometrial carcinoma do not necessarily need to have received more than two prior chemotherapeutic regimens, but may have show original
Chemotherapy administered in conjunction with primary radiation as a radiosensitizer will not be counted as a systemic chemotherapy regimen. show original
Patients who have received a single line of prior hormonal therapy with either an antiestrogen, anti-progesterone (or combination) or an aromatase inhibitor are not required to but may receive a second line of endocrine therapy show original
Age ≥ 60
% This means that the person has a very good prognosis and a low chance of experiencing any serious side effects from their cancer treatment. show original
Patients must have agreed to share their personal information with researchers. show original
Age ≥ 18 years
Prior bilateral oophorectomy
The first recorded instance of a hysterectomy was performed in 1827 by Dr show original
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 1 year
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 1 year.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Fulvestrant will improve 1 primary outcome in patients with Adenocarcinoma. Measurement will happen over the course of 1 year.

objective response rate
1 YEAR
defined as the percentage of patients with complete response (CR) + partial response (PR)]after initiating therapy. Response and progression will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1).
1 YEAR

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people get adenocarcinoma a year in the United States?

About 5.5 million cases of colorectal adenocarcinoma are diagnosed in the United States each year, making it one of the most frequently diagnosed malignancies in the country.

Anonymous Patient Answer

Can adenocarcinoma be cured?

A curative operation has not been achieved with advanced carcinoma of the rectum. However more cases need to be presented with this tumor type to make a valid statement.

Anonymous Patient Answer

What is adenocarcinoma?

Adenocarcinoma is the most common histologic subtype of carcinoma of the esophageal epithelium and the fifth most common type of esophageal carcinoma, with an overall 5-year survival rate of less than 20%. Adenocarcinomas of the esophagogastric junction are less aggressive than gastroesophageal adenocarcinoma and have a good prognosis and are more curable than distal esophageal adenocarcinoma. It is imperative that all carcinomas of the esophagus be reported and diagnosed optimally so that better long-term outcomes can be achieved.

Anonymous Patient Answer

What are the signs of adenocarcinoma?

Adenocarcinoma presents with painful or abnormal weight loss, or lump or mass on the skin. Abnormalities on blood tests include anemia and low or high white blood cells.\n\nNumerous medications are being developed to treat cancer. Some are specifically developed by chemists in order to target certain types of cancer. For example, paclitaxel, a naturally occurring chemical that causes uncontrolled cell death through the use of mitochondrial swelling, can affect many tumors. Others are drugs that are used to treat cancer, but also induce a change in the rate of normal cell growth. The two main groups of this kind include anthracyclines and antimetabolites.

Anonymous Patient Answer

What are common treatments for adenocarcinoma?

A significant challenge in cancer treatment is to identify effective therapies for particular individuals, particularly for stage IV cancer. In stage IV cancer, the survival rates are worse in women than in men. Women with stage IV disease who undergo chemotherapy had an improved survival rate than women who were not treated (21% vs 11% at 3 years, P = 0.014). Women who received chemotherapy reported significantly greater improvements in symptoms ( P = 0.007), physical functioning ( P = 0.004), and mental functioning ( P = 0.018) than women who did not undergo chemotherapy. Women also displayed a significantly greater decline in symptoms ( P = 0.018), physical functioning ( P = 0.028), and mental functioning ( P = 0.

Anonymous Patient Answer

Who should consider clinical trials for adenocarcinoma?

Patients who did not wish to receive any therapy were most likely to be eligible for clinical trials. Clinical trials for adenocarcinoma are a worthwhile investment and should be offered to patients and their families.

Anonymous Patient Answer

Is fulvestrant safe for people?

Fulvestrant may be safely administered to people over 75 years of age, but its use may be limited for people in older age groups. The risk of serious and fatal thromboembolism is very low (the risk is about 0.9%). The incidence of peripheral edema is lower than that reported in clinical trials.

Anonymous Patient Answer

What is fulvestrant?

The therapeutic efficacy of fulvestrant is related to its potentiation of the growth-inhibitory activity of ERβ in breast cancer cell lines. It does not act via other functions of the ER such as ERα/β ligand binding, and therefore may be considered a preferential ERβ agonist.

Anonymous Patient Answer

What is the average age someone gets adenocarcinoma?

Adenocarcinoma is the second most common cause of death from breast cancer; the average person is 47. If you had a [complete course of treatment for breast cancer], you might have a few years to live and to have one last big vacation.\n

Anonymous Patient Answer

Have there been any new discoveries for treating adenocarcinoma?

After almost a decade of research, the understanding of the progression of adenocarcinoma and how we can prevent it remain unsatisfying. As with many cancers, adenocarcinoma can be managed using many different treatment strategies; however, our goal remains to find therapies that selectively target adenocarcinoma without harming the surrounding normal tissue. To date, such therapies have been found using novel targeted therapies, and newer treatment strategies are also in the final stages of testing. However, because adenocarcinoma is an aggressive cancer and carries a poor prognosis, the use of targeted therapies is critical to improving outcomes for people who have it.

Anonymous Patient Answer

Does fulvestrant improve quality of life for those with adenocarcinoma?

Fulvestrant reduced pain, improved the degree of HRQOL and Q-LQPAD. There was high consistency in patient-reported HRQOL assessments. These data indicate that patients with HRQoL parameters in the low end of the spectrum may benefit from this agent. HRQoL assessment using the FACT can provide clinicians and patients with useful information about efficacy, which can be critical to the decision-making process.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Adenocarcinoma by sharing your contact details with the study coordinator.